Title : Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.

Pub. Date : 2021 Mar

PMID : 33473169






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The tyrosine kinase inhibitors (TKIs) lapatinib, neratinib, and tucatinib are FDA-approved for the treatment of HER2-positive breast cancer. Lapatinib erb-b2 receptor tyrosine kinase 2 Homo sapiens